DEF 14A: CytoSorbents Corporation Announces Annual Meeting of Stockholders to be Held Virtually on June 6, 2024

CytoSorbents Corporation will hold its annual meeting of stockholders virtually on June 6, 2024, to vote on director elections, executive compensation, an amendment to the long-term incentive plan, and ratification of the independent accounting firm.

Summary

• CytoSorbents Corporation will hold its Annual Meeting of Stockholders virtually on June 6, 2024, at 10:00 a.m. Eastern Time.
• Stockholders of record as of April 12, 2024, are entitled to vote at the meeting.
• The meeting will address the election of five directors for one-year terms, an advisory vote on executive compensation, approval of an amendment to the 2014 Long-Term Incentive Plan, and ratification of the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board of Directors recommends voting FOR all proposals.
• The company is providing access to proxy materials online to reduce paper and mailing costs.
• Stockholders can attend the virtual meeting at www.virtualshareholdermeeting.com/CTSO2024 using a 16-digit control number.
• As of the record date, April 12, 2024, there were 54,306,415 shares of Common Stock issued and outstanding.

Sentiment

Score: 7

Explanation: The document is a standard corporate communication, presenting information in a neutral and factual manner. The sentiment is moderately positive as it outlines routine corporate governance matters and seeks shareholder approval for initiatives intended to benefit the company's long-term growth.

Positives

• The virtual meeting format facilitates stockholder attendance and participation at no cost.
• Providing proxy materials online reduces paper and mailing costs.
• The proposed amendment to the 2014 Long-Term Incentive Plan is intended to meet the equity compensation needs of the company over multiple years.
• The Board believes that equity compensation is an essential element of the compensation package and that equity awards align employees and directors' interests with those of the stockholders.
• The plan includes features designed to protect stockholder interests, such as an independent administrator, no evergreen feature, repricing prohibition, and per-participant limits on awards.

Negatives

• Approval of the Plan Amendment will increase potential dilution to stockholders by 13.8% to 38.5%.

Risks

• Failure to approve the Plan Amendment may force the company to consider cash replacement alternatives to provide a market-competitive total compensation package, potentially reducing cash available for investment in growth and development.
• If the stockholders fail to ratify the selection of WithumSmith+Brown, PC, then the Audit Committee will reconsider whether or not to retain that firm.

Future Outlook

The company intends to hold future advisory votes on executive compensation annually, with the next vote expected at the annual meeting in 2025.

Management Comments

• The Board believes that its current leadership structure with Dr. Chan serving as the Chief Executive Officer and Mr. Bator serving as our independent non-executive Chairman, is appropriate for the Company at this time as it promotes balance between the Boards independent authority to oversee our business and the Chief Executive Officer and his management team who manage the business on a day-to-day basis.
• The Compensation Committee believes that long term incentives are important in supporting the key objectives of the Companys compensation program which is aimed at incentivizing through equity growth rather than cash incentives.

Industry Context

The document does not explicitly discuss the broader industry context, but it mentions that the company competes for capital with other early-stage microcap and small-cap companies in the life sciences space and competes with pharmaceutical and medical device companies in seeking to attract and retain a skilled management team.

Comparison to Industry Standards

• The Compensation Committee considers the median of the base salary range for comparable life science companies on the Nasdaq between a market cap of $200 million to $500 million.
• Radford, an Aon-Hewitt company, is used as a consultant to compare the compensation practices of the Company with peer companies in the life sciences sector.

Related Party Transactions

• There were no related party transactions in 2023.

Stakeholder Impact

• Shareholders are asked to vote on matters that directly affect the company's governance and executive compensation.
• Employees may be impacted by the approval of the long-term incentive plan amendment, which affects equity compensation.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will announce preliminary voting results at the Annual Meeting and report the final results in a Current Report on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, Long-Term Incentive Plan, WithumSmith+Brown, Virtual Meeting, CytoSorbents